Blood eosinophilia is an on-treatment biomarker in patients undergoing vaccination with dendritic cells that correlates with long-term patient outcome

Moreira A, Vass V, Erdmann M, Sponagl F, Schuler G, Schuler-Thurner B (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 25-25

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Authors with CRIS profile

Alvaro Moreira Department of Dermatology Gerold Schuler Lehrstuhl für Haut- und Geschlechtskrankheiten Beatrice Schuler-Thurner Lehrstuhl für Haut- und Geschlechtskrankheiten

How to cite

APA:

Moreira, A., Vass, V., Erdmann, M., Sponagl, F., Schuler, G., & Schuler-Thurner, B. (2019). Blood eosinophilia is an on-treatment biomarker in patients undergoing vaccination with dendritic cells that correlates with long-term patient outcome. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 25-25). HOBOKEN: WILEY.

MLA:

Moreira, Alvaro, et al. "Blood eosinophilia is an on-treatment biomarker in patients undergoing vaccination with dendritic cells that correlates with long-term patient outcome." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2019. 25-25.

BibTeX: Download